Business Wire

Patient Safety Leaders and Advocates Discuss Solutions to Eliminate Preventable Patient Deaths

Share

On the same day the World Health Organization (WHO) designated World Patient Safety Day, The Patient Safety Movement Foundation’s (PSMF) Midyear Planning Meeting (MYPM) brought together more than a hundred patient safety stakeholders from across seven countries for intimate discussions about how to achieve ZERO preventable deaths in hospitals. More than 200,000 people die due to medical errors in the US each year, and more the 4.8 million worldwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190919005264/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Patient safety leaders convened at the PSMF Midyear Planning Meeting to discuss solutions to preventable patient deaths. (Photo: Business Wire)

During this important meeting, administrators, clinicians, patient safety advocates, family members and other patient safety leaders from across the healthcare ecosystem had an opportunity to share experiences and expertise to help develop solutions to eliminate preventable patient deaths.

The meeting began with a special video message from Dr. Tedros Adhanom Ghebreyesus, Director General of the WHO thanking those who have made a commitment to patient safety and challenging others to make the same commitment to support the WHO in making patient safety a global priority.

“No one should be harmed when seeking healthcare,” said Joe Kiani, PSMF founder. “Even one preventable death is one too many. World Patient Safety Day activates every stakeholder across the healthcare ecosystem to ‘Speak up for patient safety.’ I challenge you to join us and make plans to achieve ZERO.”

During the day, general sessions demonstrated to those in attendance how individuals and organizations have changed policies and processes to eliminate preventable patient deaths.

Breakout sessions focused on solutions for:

  • Medication Safety/Opioid Safety (APSS #3 and #4)
  • Hand-Off Communications (APSS #6)
  • Neonatal Airway Safety (APSS #7 and #8)
  • Early Detection and Treatment of Sepsis (APSS #9)
  • Systemic Prevention and Resuscitation of In-Hospital Cardiac Arrest (APSS #10)
  • Mother/Baby Falls (APSS #11 and #14)
  • Embolic Events (APSS #12)
  • Person and Family Engagement and Hand Hygiene (APSS #16 and #2)
  • Patient Safety Curriculum (APSS #17)
  • Post-Operative Delirium in Older Adults (APSS #18)

“The numbers of patients that die each year from preventable hospital errors is just not acceptable, and we know how to lower them,” said David Mayer, PSMF CEO. “Our 34 free Actionable Patient Safety Solutions (APSS) provide specific processes and guidance to help hospitals prevent medical harm. We know how to reduce the number of preventable deaths on our way to eliminating them entirely.”

About Patient Safety Movement Foundation

Each year, more than 200,000 people die unnecessarily in U.S. hospitals. Worldwide, 4.8 million lives are similarly lost. The Patient Safety Movement Foundation (PSMF) is a global non-profit that offers free tools to help achieve ZERO preventable deaths from hospital errors. The Patient Safety Movement Foundation was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare to reduce that number of preventable deaths to ZERO. Improving patient safety requires a collaborative effort from all stakeholders, including patients, healthcare providers, medical technology companies, government, employers, and private payers. PSMF’s World Patient Safety, Science & Technology Summit brings together the world’s best minds for thought-provoking discussions and new ideas to challenge the status quo. Our Actionable Patient Safety Solutions (APSS) provide evidence-based processes to help hospitals eliminate errors. Our Open Data Pledge encourages healthcare technology companies to share the data for which their products are purchased. Visit patientsafetymovement.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

David Kodama
Cook + Schmid
dkodama@cookandschmid.com
619-814-2370 x17

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 14:00:00 CEST | Press release

The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin

HiddenA line styled icon from Orion Icon Library.Eye